IP Library Granted Patent US 9,487,588
Granted Patent B2
US 9,487,588 · App. 14/181,334 · Granted Nov 8, 2016

Antibodies against the ectodomain of ERBB3 and uses thereof

Inventors: Birgit Schoeberl (Cambridge, MA); Ulrik Nielsen (Quincy, MA); Michael Feldhaus (Grantham, NH); Arumugam Muruganandam (Bangalore, IN); David Buckler (Chester, NJ)
Assignee: Merrimack Pharmaceuticals, Inc.
C07K16/2863A61K31/337A61K31/517A61K33/24A61K39/3955A61K39/39558C07K16/32A61K2039/505C07K2316/96C07K2317/21C07K2317/55C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,487,588
App. No.
14/181,334
Granted
Nov 8, 2016
Kind
B2
Abstract

The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.

Claims (6)

1. An anti-ErbB3 antibody comprising a heavy chain variable region comprising SEQ ID NO:1, or an amino acid sequence at least 90% identical thereto, and a light chain variable region comprising SEQ ID NO:2, or an amino acid sequence at least 90% identical thereto, wherein the antibody binds the ectodomain of human ErbB3, and wherein the antibody comprises:

(a) variable heavy chain residues Tyr32 or Phe32, Va133, Trp57, Met102, Thr104, and Ile105 of SEQ ID NO: 1; and

(b) variable light chain residues Asp28, Tyr32 or Phe32, and Tyr93 or Phe93 of SEQ ID NO: 2.

2. The anti-ErbB3 antibody of claim 1 , wherein the antibody is an IgG2 isotype.

3. The anti-ErbB3 antibody of claim 1 , wherein the heavy and light chain variable regions comprise amino acids sequences at least 95% identical to SEQ ID NO:1 and SEQ ID NO: 2, respectively.

4. A composition comprising the antibody of claim 1 in a pharmaceutically acceptable carrier.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2019
From: MERRIMACK PHARMACEUTICALS, INC.
To: 14NER ONCOLOGY, INC.
Reel/Frame 050024/0722 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 042254/0349 →
SECURITY INTEREST Recorded Dec 28, 2015
From: MERRIMACK PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 037394/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: DYAX CORP.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034395/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: SCHOEBERL, BIRGIT; NIELSEN, ULRIK; FELDHAUS, MICHAEL
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034395/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: MURUGANANDAM, ARUMUGAM; BUCKLER, DAVID
To: DYAX CORP.
Reel/Frame 034395/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2014
From: MURUGANANDAM, ARUMUGAM; BUCKLER, DAVID
To: DYAX CORP.
Reel/Frame 033058/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2014
From: SCHOEBERL, BIRGIT; NIELSEN, ULRIK; FELDHAUS, MICHAEL
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033058/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2014
From: DYAX CORP.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033058/0365 →
Continuity (6)
Continuation 12545279 · Aug 21, 2009
Continuation In Part 12425874 · Apr 17, 2009
Continuation In Part 12281925
Provisional Application 60901904 · Feb 16, 2007
Provisional Application 61009796 · Jan 2, 2008
Related Publication 20140234329A1 · Aug 21, 2014